The impact of anogenital warts on health-related quality of life: a 6-month prospective study
- PMID: 21934571
- DOI: 10.1097/OLQ.0b013e3182215512
The impact of anogenital warts on health-related quality of life: a 6-month prospective study
Abstract
Background: The burden of anogenital warts will be a determining factor when making decisions about the type of human papillomavirus (HPV) vaccine to be used (bivalent or quadrivalent) and whether to vaccinate males. We conducted a multicenter prospective study to (1) describe the impact of anogenital warts on quality of life and (2) estimate the quality-adjusted life-years (QALYs) lost due to anogenital warts.
Methods: Between September 2006 and February 2008, 272 patients with a first or recurrent episode of anogenital warts were recruited from the clinical practices of 42 physicians across Canada. Quality of life was measured at recruitment, and 2 and 6 months later with the EuroQol, Short Form-12, short Spielberg State-Trait Anxiety Inventory, and HPV impact profile. The duration of an episode and QALYs lost due to anogenital warts were estimated among 51 incident cases recruited within 90 days of disease onset.
Results: Anogenital warts had a significant impact on the quality of life. This negative impact was similar for first and recurrent episodes, and lasted as long as lesions persisted. Anogenital warts had the greatest negative impact on usual activities, pain/discomfort, and anxiety/depression, and on self-image, sexual activity, and partner issues and possible transmission. The median duration of a first anogenital wart episode amongst incident cases was 125 days and resulted in QALYs lost of 0.017 to 0.041, which is equivalent to 6 to 15 days of healthy life lost.
Conclusions: The burden of anogenital warts is substantial and should be considered by physicians and public health officials when making recommendations about HPV vaccination..
Similar articles
-
Comparative cost-effectiveness of the quadrivalent and bivalent human papillomavirus vaccines: a transmission-dynamic modeling study.Vaccine. 2013 Aug 20;31(37):3863-71. doi: 10.1016/j.vaccine.2013.06.064. Epub 2013 Jul 3. Vaccine. 2013. PMID: 23830974
-
Psychological burden of anogenital warts.J Eur Acad Dermatol Venereol. 2009 Sep;23(9):1035-8. doi: 10.1111/j.1468-3083.2009.03242.x. Epub 2009 Mar 11. J Eur Acad Dermatol Venereol. 2009. PMID: 19470067
-
Loss of quality of life associated with genital warts: baseline analyses from a prospective study.Sex Transm Infect. 2011 Apr;87(3):209-15. doi: 10.1136/sti.2009.039982. Epub 2011 Feb 18. Sex Transm Infect. 2011. PMID: 21335602
-
The prophylactic role for the human papillomavirus quadrivalent vaccine in males.Ann Pharmacother. 2010 Jul-Aug;44(7-8):1314-8. doi: 10.1345/aph.1P017. Epub 2010 May 25. Ann Pharmacother. 2010. PMID: 20501891 Review.
-
Human papillomavirus, genital warts, and vaccines.J Microbiol Immunol Infect. 2009 Apr;42(2):101-6. J Microbiol Immunol Infect. 2009. PMID: 19597640 Review.
Cited by
-
Increased incidence of genital warts among women and men with type 1 diabetes compared with the general population-results from a nationwide registry-based, cohort study.Acta Diabetol. 2022 Jan;59(1):105-112. doi: 10.1007/s00592-021-01786-8. Epub 2021 Sep 9. Acta Diabetol. 2022. PMID: 34499240
-
Systematic review of the incidence and prevalence of genital warts.BMC Infect Dis. 2013 Jan 25;13:39. doi: 10.1186/1471-2334-13-39. BMC Infect Dis. 2013. PMID: 23347441 Free PMC article.
-
Genital warts and women's sexual challenges: is sexual compatibility possible? A qualitative study.BMC Womens Health. 2023 Nov 16;23(1):610. doi: 10.1186/s12905-023-02771-9. BMC Womens Health. 2023. PMID: 37974155 Free PMC article.
-
Health and Economic Impact of Switching from a 4-Valent to a 9-Valent HPV Vaccination Program in the United States.J Natl Cancer Inst. 2015 Oct 4;108(1):djv282. doi: 10.1093/jnci/djv282. Print 2016 Jan. J Natl Cancer Inst. 2015. PMID: 26438574 Free PMC article.
-
The psychosocial burden of anogenital warts on Syrian patients: study of quality of life.Heliyon. 2022 Jun 30;8(7):e09816. doi: 10.1016/j.heliyon.2022.e09816. eCollection 2022 Jul. Heliyon. 2022. PMID: 35815151 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical